Strides Plans Re-Entry On Injectables

A non-compete agreement with Mylan ends in December

 
• By Vibha Ravi

Indian firm Strides to invest up to $40m in acquired Stelis for re-entry into generic injectables and multiple biosimilar APIs as it looks to build its business.

ine conveyor for labeling and packaging ampoules in boxes
Strides Moves Back Into Injectables • Source: Shutterstock

More from Business

More from Generics Bulletin